Resultados globales: 4 registros encontrados en 0.03 segundos.
Artículos, Encontrados 4 registros
Artículos Encontrados 4 registros  
1.
11 p, 3.4 MB PIVOT-12 : a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence / Eggermont, Alexander M. (Princess Máxima Center for Pediatric Oncology & University Medical Center Utrecht) ; Ascierto, Paolo A. (Istituto Nazionale Tumori IRCCS Fondazione G Pascale) ; Khushalani, Nikhil I. (H Lee Moffitt Cancer Center & Research Institute) ; Schadendorf, Dirk (West German Cancer Center at the University Hospital Essen) ; Boland, Genevieve (Massachusetts General Hospital (Boston)) ; Weber, Jeffrey (Perlmutter Cancer Center at NYU Langone Health) ; Lewis, Karl D. (University of Colorado Cancer Center) ; Johnson, Daniel (Ochsner Medical Center) ; Rivalland, Gareth (University of Auckland & Auckland City Hospital) ; Khattak, Adnan (Hollywood Private Hospital. Edith Cowan University) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Gogas, Helen (National & Kapodistrian University of Athens) ; Long, Georgina V. (Melanoma Institute Australia. University of Sydney. Royal North Shore & Mater Hospitals) ; Currie, Sue L. (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Chien, David (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Tagliaferri, Mary A. (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Carlino, Matteo S. (Westmead & Blacktown Hospitals & Melanoma Institute Australia. University of Sydney) ; Diab, Adi (University of Texas MD Anderson Cancer Center)
Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. [...]
2022 - 10.2217/fon-2021-1286
Future oncology (London, England), Vol. 18 Núm. 8 (january 2022) , p. 903-913  
2.
5 p, 332.1 KB Biosimilars : a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers / Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Vyas, Malvika (European Society for Medical Oncology) ; Giuliani, Rosa (San Camillo Forlanini Hospital) ; Arnold, Dirk (CUF Hospitals) ; Cardoso, Fatima (Champalimaud Clinical Center) ; Casali, Paolo Giovanni (Fondazione IRCCS National Cancer Institute) ; Cervantes, Andrés (Clinic Hospital) ; Eggermont, Alexander (Gustave Roussy Cancer Campus Grand Paris) ; Eniu, Alexandru (Cancer Institute "Ion Chiricuta") ; Jassem, Jacek (Medical University of Gdansk) ; Pentheroudakis, George (University of Ioannina) ; Peters, Solange (Centre Hospitalier Universitaire Vaudois) ; Rauh, Stefan (Hospital Center Emile Mayrisch) ; Zielinski, Christoph C. (Medical University of Vienna) ; Stahel, Rolf A. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Voest, Emile (University Hospital Zurich (Suïssa)) ; Douillard, Jean-Yves (European Society for Medical Oncology) ; McGregor, Keith (European Society for Medical Oncology) ; Ciardiello, Fortunato (Second University of Naples) ; Universitat Autònoma de Barcelona
Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems. [...]
2017 - 10.1136/esmoopen-2016-000142
ESMO open, Vol. 1 (january 2017)  
3.
4 p, 147.6 KB Towards a Cancer Mission in Horizon Europe / Berns, Anton (European Academy of Cancer Sciences) ; Ringborg, Ulrik (Karolinska University Hospital and Karolinska Institutet (Suècia)) ; Eggermont, Alexander (Gustave Roussy Cancer Campus Grand Paris) ; Baumann, Michael (German Cancer Consortium) ; Calvo, Fabien (Gustave Roussy Cancer Campus Grand Paris) ; Eggert, Angelika (Charité - Universitätsmedizin Berlin) ; Espina, Carolina (International Agency for Research on Cancer) ; Hanahan, Douglas (Federal Institute of Technology in Lausanne) ; Lacombe, Denis (EORTC Headquarters) ; De Lorenzo, Francesco (European Cancer Patient Coalition) ; Oberst, Simon (Organisation of European Cancer Institutes) ; Philip, Thierry (Institut Curie) ; Schüz, Joachim (International Agency for Research on Cancer) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Celis, Julio E. (Danish Cancer Society Research Centre) ; Universitat Autònoma de Barcelona
2019 - 10.1002/1878-0261.12585
Molecular Oncology, Vol. 13 (october 2019) , p. 2301-2304  
4.
14 p, 4.6 MB A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer / Lazar, Vladimir (Gustave-Roussy Cancer Center (France)) ; Rubin, Eitan (Ben-Gurion University of the Negev (Israel)) ; Depil, Stephane (Leon Berard Cancer Center (France)) ; Pawitan, Yudi (Karolinska Institutet (Estocolm, Suècia)) ; Martini, Jean-François (Pfizer Oncology Research (USA)) ; Gomez-Navarro, Jesus (Takeda Pharmaceuticals International Co.(USA)) ; Yver, Antoine (AstraZeneca Pharmaceuticals LP (USA)) ; Kan, Zhengyin (Pfizer Oncology Research (USA)) ; Dry, Jonathan R. (AstraZeneca Pharmaceuticals LP (USA)) ; Kehren, Jeanne (Sanofi (France)) ; Validire, Pierre (Institut Mutualiste Montsouris (France)) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Vielh, Philippe (Gustave-Roussy Cancer Center (France)) ; Ducreux, Michel (Gustave-Roussy Cancer Center (France)) ; Galbraith, Susan (AstraZeneca Pharmaceuticals LP (USA)) ; Lehnert, Manfred (Takeda Pharmaceuticals International Co. (USA)) ; Onn, Amir (Chaim Sheba Medical Center (Israel)) ; Berger, Raanan (Chaim Sheba Medical Center (Israel)) ; Pierotti, Marco A. (Fondazione IRCCS Istituto Nazionale dei Tumori (Italy)) ; Porgador, Angel (Ben-Gurion University of the Negev (Israel)) ; Pramesh, C. S. (Tata Memorial Centre (India)) ; Ye, Ding-wei (Fudan University Shanghai Cancer Center (China)) ; Carvalho, Andre L. (Barretos Cancer Hospital. Fundacao Pio XII (Brazil)) ; Batist, Gerald (Jewish General Hospita. Segal Cancer Centre (Canada)) ; Le Chevalier, Thierry (Gustave-Roussy Cancer Center (France)) ; Morice, Philippe (Gustave-Roussy Cancer Center (France)) ; Besse, Benjamin (Gustave-Roussy Cancer Center (France)) ; Vassal, Gilles (Gustave-Roussy Cancer Center (France)) ; Mortlock, Andrew (AstraZeneca Pharmaceuticals LP (USA)) ; Hansson, Johan (Karolinska Institutet (Estocolm, Suècia)) ; Berindan Neagoe, Ioana (Universitatea de Medicină şi Farmacie Iuliu Haţieganu Cluj-Napoca (Romania)) ; Dann, Robert (General Electric Healthcare (USA)) ; Haspel, Joel (Oracle Corporation (UK)) ; Irimie, Alexandru (Universitatea de Medicină şi Farmacie Iuliu Haţieganu Cluj-Napoca (Romania)) ; Laderman, Steve (Agilent Technologies (USA)) ; Nechushtan, Hovav (Hadassah Hebrew University Medical Center (Israel)) ; Al Omari, Amal S. (King Hussein Cancer Center (Jordan)) ; Haywood, Trent (Blue Cross Blue Shield Association (USA)) ; Bresson, Catherine (WIN Consortium (France)) ; Soo, Khee Chee (National Cancer Centre (Singapore)) ; Osman, Iman (New York University Langone Medical Center (USA)) ; Mata, Hilario (MD Anderson Cancer Center (USA)) ; Lee, Jack J. (MD Anderson Cancer Center (USA)) ; Jhaveri, Komal (New York University Langone Medical Center (USA)) ; Meurice, Guillaume (Gustave-Roussy Cancer Center (France)) ; Palmer, Gary (Foundation Medicine Inc. (USA)) ; Lacroix, Ludovic (Gustave-Roussy Cancer Center (France)) ; Koscielny, Serge (Gustave-Roussy Cancer Center (France)) ; Eterovic, Karina Agda (MD Anderson Cancer Center (USA)) ; Blay, Jean-Yves (Leon Berard Cancer Center (France)) ; Buller, Richard (Pfizer Oncology Research (USA)) ; Eggermont, Alexander (Gustave-Roussy Cancer Center (France)) ; Schilsky, Richard L. (American Society of Clinical Oncology (USA)) ; Mendelsohn, John (MD Anderson Cancer Center (USA)) ; Soria, Jean-Charles (Gustave-Roussy Cancer Center (France)) ; Rothenberg, Mace (Pfizer Oncology Research (USA)) ; Scoazec, Jean-Yves (Gustave-Roussy Cancer Center (France)) ; Ki Hong, Waun (MD Anderson Cancer Center (USA)) ; Kurzrock, Razelle (Moores Cancer Center (USA)) ; Universitat Autònoma de Barcelona
Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. Targeted monotherapies produce high regression rates, albeit for limited patient subgroups, who inevitably succumb. We present a novel strategy for identifying customized combinations of triplets of targeted agents, utilizing a simplified interventional mapping system (SIMS) that merges knowledge about existent drugs and their impact on the hallmarks of cancer. [...]
2015 - 10.18632/oncotarget.3741
Oncotarget, Vol. 6, no. 16 (June 2015) , p. 14139-14152  

Vea también: autores con nombres similares
1 Eggermont, A.
1 Eggermont, Alexander M.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.